Breakthroughs in rare disease research often begin as bold, unconventional ideas—ideas that do not always fit neatly into narrowly defined requests for applications or traditional funding cycles. Since its founding, the Neurofibromatosis Therapeutic Acceleration Program […]
The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is pleased to announce updates to the Open Proposal Grant Program—designed to accelerate the development of effective therapies for NF1-associated peripheral nerve sheath tumors, including cutaneous (cNF), plexiform (pNF), […]
It can spawn tumors throughout the nervous system and bone deformities that riddle the whole body with pain. One of the most common rare diseases in the world, the genetic condition neurofibromatosis type 1, or NF1, can cause a wide spectrum of mild to severe symptoms—all stemming from a single mutation on a solitary gene: the NF1 gene on chromosome 17.
In response to a critical funding gap affecting the NF1 research community, the Neurofibromatosis Therapeutic Acceleration Program (NTAP) has launched a new training initiative: the NF1 Basic and Translational Laboratory Scholars Program. This program is […]
NTAP’s innovative funding approach was featured in an article,”Pedal to the Metal” on Inside Hopkins, the Johns Hopkins Medicine daily publication highlighting exceptional and impactful programs. “How an innovative funding approach is advancing research and […]
The Neurofibromatosis Therapeutic Acceleration Program (NTAP) at the Johns Hopkins University School of Medicine is proud to announce that Dr. Nicole Brossier, Dr. Suganth Suppiah, and Dr. Harish Vasudevan have been selected as the 2021 […]
